Skip to main content

Month: March 2025

Martinrea International Inc. Publishes 2024 Sustainability Report

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) — Martinrea International Inc. (TSX : MRE), a diversified and global automotive supplier engaged in the design, development, and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, announced the release of its 2024 Sustainability Report on March 6, 2025. “As a Company, we recognize in order to ‘Leave It Better,’ we need to focus on creative and innovative approaches to sustainability,” said Pat D’Eramo, CEO. “Our team continues to drive advancements in product development, manufacturing efficiencies and technology implementation, ensuring we adapt to an ever-evolving industry while creating a more sustainable future.” “Our commitment to ‘Making People’s Lives Better’ is at the core of everything we do,” said Rob Wildeboer, Executive Chairman. “This...

Continue reading

Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent

Hamilton, March 07, 2025 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (OTCQB:CYTOF) today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for a patent (application #17/466,142) relating to the composition of Bentrio®, a nasal spray developed and commercialized by its affiliate Altamira Medica AG (“Medica”) for preventing or treating allergic rhinitis. The claims are directed to the key ingredients and composition of Bentrio’s proprietary formulation. The patent, upon issuance, will have an initial priority date of September 8, 2020, and is expected to provide key intellectual property protection for Bentrio in the USA, the world’s largest market for “over the counter (OTC)” products for allergic rhinitis relief and treatment. “We are very pleased to have achieved this...

Continue reading

Changes in Inbank Articles of Association

AS Inbank has proposed the following amendments to the Inbank Articles of Association for approval at the Annual General Meeting of Shareholders on 31 March 2025: 6.3 The Supervisory Board has a right, within 3 (three) years as of the entry into force of the version of the articles of association, to increase the share capital by monetary contributions by EUR 76,000, i.e. to increase the share capital to the amount of EUR 1,227,966.30. 7.9 The Bank may be represented in transactions and legal operations by two members of the Management Board jointly. A person acting in the name of the Bank may not represent the Bank in concluding transactions or holding legal disputes with a third person with regard to whom the person acting in the name of the Bank or a person with an economic interest equivalent to that of such person has personal economic...

Continue reading

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts

Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that the lead program of the Company, AVA6000, the first clinical stage asset which is a pre|CISION®-enabled form of doxorubicin, has completed the Phase 1a dose escalation with encouraging PFS data in patients with salivary gland cancers. The Company has initiated enrollment in the Phase 1b expansion cohorts with multiple patients treated. Promising early efficacy and safety signals are observed in the Phase 1a trial. As of the most recent data...

Continue reading

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that Capricor management will participate in one-on-one investor meetings and provide a corporate update at Leerink’s Global Healthcare Conference 2025, taking place March 10-12, 2025 in Miami, Florida. Leerink’s Global Healthcare Conference 2025Presentation Date: Wednesday, March 12, 2025 Time: 1:00-1:40 p.m. ET Webcast: Click hereCapricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates. For further information on this presentation, please visit Capricor’s website...

Continue reading

Annual Financial Statements of Orkuveitan | Robust Growth and Solid Performance

Orkuveitan has published its consolidated financial statements for the year 2024, presenting highly positive results. The Group’s profit increased by 45% from 2023, amounting to ISK 9.3 billion. A dividend proposal of ISK 6.5 billion has been put forth. The Group comprises the parent company, Veitur, Orka náttúrunnar, Ljósleiðarinn, and Carbfix. Its shareholders are the City of Reykjavík, the Municipality of Akranes, and the Municipality of Borgarbyggð. “The excellent operating results last year provide a strong foundation for Orkuveitan’s new phase of growth,” says CEO Sævar Freyr Þráinsson. “We have met significant demand for our services and will continue to invest responsibly in innovation, sustainability, and robust infrastructure.” Steady Growth and Increased Investments The Group’s revenue rose 9.2% from 2023 to 2024, while operating...

Continue reading

Enstar Subsidiary Assigned “A” Financial Strength Rating by AM Best

HAMILTON, Bermuda, March 07, 2025 (GLOBE NEWSWIRE) — Enstar Group Limited (NASDAQ: ESGR) announced today that the credit rating agency AM Best has assigned a Financial Strength Rating of “A” (Excellent) and a Long-Term Issuer Credit Rating (Long-Term ICR) of “a+” (Excellent) to Cavello Bay Reinsurance Limited (Cavello Bay), a subsidiary of Enstar Group Limited (Enstar) and its primary non-life run-off consolidator and a Class 3B reinsurer. The outlook assigned to these Credit Ratings is stable. On issuing its rating, AM Best highlighted Enstar’s “long track record of effectively managing claims in complicated lines of business”, noting that the ratings reflect Enstar’s balance sheet strength, as well as its strong operating performance, which it believes should remain at the current level throughout the remainder of 2025. Matt...

Continue reading

MAX Power Expands Geological and Engineering Team for Natural Hydrogen in Saskatchewan

VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) — MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”) is pleased to announce important new additions to the Company’s technical team to accelerate a North American-leading program for Natural Hydrogen exploration and development in Saskatchewan where historical data and work carried out by MAX Power point to game-changing possibilities for this rapidly emerging sector. Prairie Hunter Exploration Ltd. (PHEL) Prairie Hunter is a Saskatchewan-based geoscience and exploration consulting and advisement corporation owned and managed by Mr. Stephen Halabura, M.Sc., P.Geo., FEC (Hon.), FGC. Mr. Halabura has decades of successful experience in the province’s resource sector and has a deep understanding of the geological controls on the...

Continue reading

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting

Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹Shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L. Sawyers and William T. Winters did not stand for re-electionShareholders approved all other proposals by the Board of Directors, including the reduction of share capital, the 2024 report on non-financial matters and the 2024 Compensation Report, as well as the future Board and Executive Committee compensation in separate binding votesBasel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1,693...

Continue reading

Northfield Capital Champions Canadian Craftsmanship With Spirit of York Distillery Co., the Official Gin of Live Nation In Ontario

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) — Northfield Capital Corporation (TSX-V: NFD.A) (“Northfield” or the “Corporation”), a proudly Canadian-owned investment company, is reaffirming its commitment to Canadian industry and craftsmanship through its strategic leadership and ownership of Spirit of York Distillery Co. (or “Spirit of York”). Rooted in national pride, Spirit of York is setting the benchmark for premium Canadian spirits, sourcing 100% of its ingredients – including heritage grains and pristine water – from within Canada. As the Official Gin of Live Nation Canada, Inc. in Ontario (or “Live Nation”), Spirit of York is taking center stage at some of the province’s most iconic music venues and festivals. This three-year partnership, launched in 2024, brings Spirit of York Premium Gin to concertgoers at four...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.